ALB and left ventricular hypertrophy: We therefore mounted the double-blind placebo-controlled ANTI-MASK Trial (NCT02893358) to assess whether in patients with masked hypertension BP lowering treatment for 1 year would improve TOD, as captured by brachial-ankle pulse wave velocity (baPWV),10 the urinary albumin-to-creatinine ratio (ACR), and electrocardiographic left ventricular hypertrophy.